Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.

Trial Profile

Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Cabazitaxel (Primary) ; Antineoplastics
  • Indications Bladder cancer; Carcinoma
  • Focus Therapeutic Use
  • Acronyms CabB1
  • Most Recent Events

    • 06 Jun 2017 Results (n=20) assessing efficacy of Cabazitaxel, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 26 Feb 2013 Planned end date changed from 1 Dec 2015 to 31 Dec 2015 as reported by ISRCTN: Current Controlled Trials record.
    • 26 Feb 2013 New source identified and integrated (ISRCTN: Current Controlled Trials; 76947550).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top